{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:18:03Z","timestamp":1792459083158,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T00:00:00Z","timestamp":1338854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/nrneph.2012.107","type":"journal-article","created":{"date-parts":[[2012,6,5]],"date-time":"2012-06-05T13:51:34Z","timestamp":1338904294000},"page":"523-532","source":"Crossref","is-referenced-by-count":48,"title":["Complications of long-term therapy for ANCA-associated systemic vasculitis"],"prefix":"10.1038","volume":"8","author":[{"given":"Nadezhda","family":"Wall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,5]]},"reference":[{"key":"BFnrneph2012107_CR1","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12016-011-8258-y","volume":"41","author":"CGM Kallenberg","year":"2011","unstructured":"Kallenberg, C. G. M. Pathogenesis of ANCA-associated vasculitis, an update. Clin. Rev. Allergy Immunol. 41, 224\u2013231 (2011).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"BFnrneph2012107_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/art.20928","volume":"53","author":"E Reinhold-Keller","year":"2005","unstructured":"Reinhold-Keller, E., Herlyn, K., Wagner-Bastmeyer, R. & Gross, W. L. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum. 53, 93\u201399 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s11926-005-0036-5","volume":"7","author":"SE Lane","year":"2005","unstructured":"Lane, S. E., Watts, R. & Scott, D. G. I. Epidemiology of systemic vasculitis. Curr. Rheumatol. Rep. 7, 270\u2013275 (2005).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrneph2012107_CR4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/rheumatology\/keh522","volume":"44","author":"L Harper","year":"2005","unstructured":"Harper, L. & Savage, C. O. ANCA-associated renal vasculitis at the end of the twentieth century\u2014a disease of older patients. Rheumatology 44, 495\u2013501 (2005).","journal-title":"Rheumatology"},{"key":"BFnrneph2012107_CR5","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","volume":"2","author":"EW Walton","year":"1958","unstructured":"Walton, E. W. Giant-cell granuloma of the respiratory tract (Wegeners granulomatosis). Br. Med. J. 2, 265\u2013270 (1958).","journal-title":"Br. Med. J."},{"key":"BFnrneph2012107_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1365-2796.2008.02060.x","volume":"265","author":"P Eriksson","year":"2009","unstructured":"Eriksson, P., Jacobsson, L., Lindell, A., Nilsson, J. A. & Skogh, T. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. J. Int. Med. 265, 496\u2013506 (2009).","journal-title":"J. Int. Med."},{"key":"BFnrneph2012107_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/039463200802100317","volume":"21","author":"P Stratta","year":"2008","unstructured":"Stratta, P. et al. Improvement in relative survival of patients with vasculitis: study of 101 cases compared to the general population. Int. J. Immunopathol. Pharmacol. 21, 631\u2013642 (2008).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"BFnrneph2012107_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488\u2013494 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/art.27763","volume":"63","author":"JU Holle","year":"2011","unstructured":"Holle, J. U. et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 63, 257\u2013266 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jama.298.6.655","volume":"298","author":"X Bosch","year":"2007","unstructured":"Bosch, X., Guilabert, A., Espinosa, G. & Mirapeix, E. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis\u2014a systematic reviw. JAMA 298, 655\u2013669 (2007).","journal-title":"JAMA"},{"key":"BFnrneph2012107_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ard.2008.088096","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C. et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 68, 310\u2013317 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR12","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/rheumatology\/kem146a","volume":"46","author":"C Lapraik","year":"2007","unstructured":"Lapraik, C. et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology 46, 1615\u20131616 (2007).","journal-title":"Rheumatology"},{"key":"BFnrneph2012107_CR13","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/ard.2007.071936","volume":"67","author":"C Mukhtyar","year":"2008","unstructured":"Mukhtyar, C. et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 67, 1004\u20131010 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","volume":"96","author":"H Sch\u00e4cke","year":"2002","unstructured":"Sch\u00e4cke, H., D\u00f6cke, W.-D. & Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96, 23\u201343 (2002).","journal-title":"Pharmacol. Ther."},{"key":"BFnrneph2012107_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.berh.2009.04.002","volume":"23","author":"J Turnbull","year":"2009","unstructured":"Turnbull, J. & Harper, L. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract. Res. Clin. Rheumatol. 23, 391\u2013401 (2009).","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"BFnrneph2012107_CR16","first-page":"253","volume":"6","author":"S Hamour","year":"2010","unstructured":"Hamour, S., Salama, A. D. & Pusey, C. D. Management of ANCA-associated vasculitis: Current trends and future prospects. Ther. Clin. Risk Manag. 6, 253\u2013264 (2010).","journal-title":"Ther. Clin. Risk Manag."},{"key":"BFnrneph2012107_CR17","doi-asserted-by":"publisher","first-page":"S660","DOI":"10.1002\/art.10839","volume":"48","author":"K de Groot","year":"2003","unstructured":"de Groot, K. et al. DRW for EUVAS. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in non-renal ANCA-associated vasculitis. Arthritis Rheum. 48, S660\u2013S660 (2003).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/BOR.0b013e32834120c1","volume":"23","author":"A Casian","year":"2011","unstructured":"Casian, A. & Jayne, D. Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and renal limited vasculitis. Curr. Opin. Rheumatol. 23, 12\u201317 (2011).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrneph2012107_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.transci.2008.09.003","volume":"39","author":"B Stegmayr","year":"2008","unstructured":"Stegmayr, B. et al. World apheresis registry 2003\u20132007 data. Transfus. Apher. Sci. 39, 247\u2013254 (2008).","journal-title":"Transfus. Apher. Sci."},{"key":"BFnrneph2012107_CR20","first-page":"415","volume":"31","author":"M Rufino Hernandez","year":"2011","unstructured":"Rufino Hernandez, M. et al. Patients treated with plasmapheresis: a case review from University Hospital of the Canary Islands. Nefrologia 31, 415\u2013434 (2011).","journal-title":"Nefrologia"},{"key":"BFnrneph2012107_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.7861\/clinmedicine.6-4-343","volume":"6","author":"K Ei-Ghariani","year":"2006","unstructured":"Ei-Ghariani, K. & Unsworth, D. J. Therapeutic apheresis\u2014plasmapheresis. Clin. Med. 6, 343\u2013347 (2006).","journal-title":"Clin. Med."},{"key":"BFnrneph2012107_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/jca.2920030209","volume":"3","author":"L Wood","year":"1986","unstructured":"Wood, L. & Jacobs, P. The effect of serial therapeutic plasmapheresis on platelet count, coagulation factors, plasma immunoglobulin, and complement levels. J. Clin. Apher. 3, 124\u2013128 (1986).","journal-title":"J. Clin. Apher."},{"key":"BFnrneph2012107_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/rheumatology\/kem029","volume":"46","author":"C Metzler","year":"2007","unstructured":"Metzler, C. et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's gyranulomatosis. Rheumatology 46, 1087\u20131091 (2007).","journal-title":"Rheumatology"},{"key":"BFnrneph2012107_CR24","first-page":"51","volume":"164","author":"A Berden","year":"2011","unstructured":"Berden, A. et al. Long-term renal outcome of patients enrolled in the CYCAZAREM trial. Clin. Exp. Immunol. 164, 51 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneph2012107_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne, D. et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 349, 36\u201344 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012107_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0002-9343(03)00077-9","volume":"114","author":"CA Langford","year":"2003","unstructured":"Langford, C. A., Talar-Williams, C., Barron, K. S. & Sneller, M. C. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am. J. Med. 114, 463\u2013469 (2003).","journal-title":"Am. J. Med."},{"key":"BFnrneph2012107_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/rheumatology\/kel216a","volume":"47","author":"K Chakravarty","year":"2008","unstructured":"Chakravarty, K. et al. BSR\/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British association of dermatologists. Rheumatology 47, 924\u2013925 (2008).","journal-title":"Rheumatology"},{"key":"BFnrneph2012107_CR28","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2217\/pgs.11.32","volume":"12","author":"WG Newman","year":"2011","unstructured":"Newman, W. G. et al. A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics 12, 815\u2013826 (2011).","journal-title":"Pharmacogenomics"},{"key":"BFnrneph2012107_CR29","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra, T. F. et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis a randomzed controlled trial. JAMA 304, 2381\u20132388 (2010).","journal-title":"JAMA"},{"key":"BFnrneph2012107_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211\u2013220 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012107_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221\u2013232 (2010).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012107_CR32","first-page":"59","volume":"164","author":"M Helena","year":"2011","unstructured":"Helena, M. et al. Hypogammaglobulinaemia and infections following RTX therapy for systemic vasculitis and SLE. Clin. Exp. Immunol. 164, 59\u201360 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneph2012107_CR33","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch, M. H. et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 909\u2013920 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR34","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1093\/rheumatology\/ker106a","volume":"50","author":"M Bukhari","year":"2011","unstructured":"Bukhari, M. et al. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology 50, 2311\u20132313 (2011).","journal-title":"Rheumatology"},{"key":"BFnrneph2012107_CR35","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/art.30427","volume":"63","author":"D Tesfa","year":"2011","unstructured":"Tesfa, D. et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 63, 2209\u20132214 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1586\/ehm.11.62","volume":"4","author":"D Tesfa","year":"2011","unstructured":"Tesfa, D. & Palmblad, J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev. Hematol. 4, 619\u2013625 (2011).","journal-title":"Expert Rev. Hematol."},{"key":"BFnrneph2012107_CR37","doi-asserted-by":"publisher","first-page":"C89","DOI":"10.1159\/000319655","volume":"117","author":"MD Morgan","year":"2011","unstructured":"Morgan, M. D., Drayson, M. T., Savage, C. O. S. & Harper, L. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin. Pract. 117, C89\u2013C97 (2011).","journal-title":"Nephron Clin. Pract."},{"key":"BFnrneph2012107_CR38","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"JH Stone","year":"2005","unstructured":"Stone, J. H. et al. Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med. 352, 351\u2013361 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012107_CR39","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth, A. D. et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. 41, 776\u2013784 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2012107_CR40","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","volume":"69","author":"MA Little","year":"2010","unstructured":"Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036\u20131043 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR41","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/MD.0b013e3181568ec0","volume":"86","author":"A Villa-Forte","year":"2007","unstructured":"Villa-Forte, A. et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis\u2014a 12-year single-practice experience. Medicine 86, 269\u2013277 (2007).","journal-title":"Medicine"},{"key":"BFnrneph2012107_CR42","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/1529-0131(199908)42:8<1752::AID-ANR26>3.0.CO;2-6","volume":"42","author":"B Hellmich","year":"1999","unstructured":"Hellmich, B., Schanbel, A. & Gross, W. L. Granulocyte colony-stimulating factor treatment for cyclophosphamide-induced severe neutropenia in Wegener's granulomatosis. Arthritis Rheum. 42, 1752\u20131756 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR43","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/ard.2008.088302","volume":"68","author":"C Charlier","year":"2009","unstructured":"Charlier, C. et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann. Rheum. Dis. 68, 658\u2013663 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR44","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","volume":"43","author":"E Reinhold-Keller","year":"2000","unstructured":"Reinhold-Keller, E. et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis\u2014long-term outcome in 155 patients. Arthritis Rheum. 43, 1021\u20131032 (2000).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR45","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"116","author":"GS Hoffman","year":"1992","unstructured":"Hoffman, G. S. et al. Wegener granulomatosis\u2014an analysis of 158 patients. Ann. Intern. Med. 116, 488\u2013498 (1992).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2012107_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/j.1365-2249.2011.04321.x","volume":"164","author":"RB Jones","year":"2011","unstructured":"Jones, R. B., Walsh, M., Jayne, D. R. W. & European Vasculitis Study, G. Two-year follow-up results from a randomized trial of RTX versus CyP for ANCA-associated renal vasculitis: RITUXVAS. Clin. Exp. Immunol. 164, 57\u201358 (2011).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneph2012107_CR47","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard.2007.077461","volume":"67","author":"S Oren","year":"2008","unstructured":"Oren, S. et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann. Rheum. Dis. 67, 937\u2013941 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","volume":"62","author":"CO Bingham","year":"2010","unstructured":"Bingham, C. O. et al. Immunization responses in rheumatoid arthritis patients treated with rituximab results from a controlled clinical trial. Arthritis Rheum. 62, 64\u201374 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR49","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/ndt\/gfm640","volume":"23","author":"PM Stassen","year":"2008","unstructured":"Stassen, P. M., Sanders, J.-S. F., Kallenberg, C. G. M. & Stegeman, C. A. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant. 23, 654\u2013658 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2012107_CR50","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1136\/ard.2008.092924","volume":"68","author":"A Holvast","year":"2009","unstructured":"Holvast, A. et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann. Rheum. Dis. 68, 873\u2013878 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR51","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/ard.2010.137216","volume":"70","author":"S van Assen","year":"2011","unstructured":"van Assen, S. et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 70, 414\u2013422 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR52","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1016\/S0041-1345(02)03514-5","volume":"34","author":"M Koselj-Kajtna","year":"2002","unstructured":"Koselj-Kajtna, M., Koselj, M., Rott, T., Kandus, A. & Bren, A. Infectious complications of immunosuppressive treatment for anti-neutrophil cytoplasm antibody-related vasculitis. Transplant. Proc. 34, 3001\u20133002 (2002).","journal-title":"Transplant. Proc."},{"key":"BFnrneph2012107_CR53","first-page":"S51","volume":"28","author":"M Laudien","year":"2010","unstructured":"Laudien, M. et al. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener's granulomatosis as compared to rheumatoid arthritis and chronic rhinosinusitis with nasal polyps. Clin. Exp. Rheumatol. 28, S51\u2013S55 (2010).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrneph2012107_CR54","doi-asserted-by":"publisher","unstructured":"van Rijen, M., Bonten, M., Wenzel, R. & Kluytmans, J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD006216. http:\/\/dx.doi.org\/10.1002\/14651858.CD006216.pub2 .","DOI":"10.1002\/14651858.CD006216.pub2"},{"key":"BFnrneph2012107_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2826","volume":"11","author":"F Moosig","year":"2009","unstructured":"Moosig, F., Holle, J. U. & Gross, W. L. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res. Ther. 11, 1\u201311 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrneph2012107_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1056\/NEJM199607043350103","volume":"335","author":"CA Stegeman","year":"1996","unstructured":"Stegeman, C. A., Tervaert, J. W. C., deJong, P. E. & Kallenberg, C. G. M. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. N. Engl. J. Med. 335, 16\u201320 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012107_CR57","first-page":"795","volume":"151","author":"FP Ognibene","year":"1995","unstructured":"Ognibene, F. P. et al. Pneumocystis-carinii pneumonia\u2014a major complication of immunosuppressive therapy in patients with wegeners granulomatosis. Am. J. Respir. Crit. Care Med. 151, 795\u2013799 (1995).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFnrneph2012107_CR58","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/1529-0131(199904)42:4<780::AID-ANR23>3.0.CO;2-M","volume":"42","author":"MM Ward","year":"1999","unstructured":"Ward, M. M. & Donald, F. Pneumocystis carinii pneumonia in patients with connective tissue diseases\u2014the role of hospital experience in diagnosis and mortality. Arthritis Rheum. 42, 780\u2013789 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR59","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10067-006-0441-9","volume":"26","author":"ME Falagas","year":"2007","unstructured":"Falagas, M. E., Manta, K. G., Betsi, G. I. & Pappas, G. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin. Rheumatol. 26, 663\u2013670 (2007).","journal-title":"Clin. Rheumatol."},{"key":"BFnrneph2012107_CR60","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/art.1780401213","volume":"40","author":"L Guillevin","year":"1997","unstructured":"Guillevin, L. et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum. 40, 2187\u20132198 (1997).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-4-42","volume":"4","author":"E Sowden","year":"2004","unstructured":"Sowden, E. & Carmichael, A. J. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC Infect. Dis. 4, 1\u20136 (2004).","journal-title":"BMC Infect. Dis."},{"key":"BFnrneph2012107_CR62","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/infdis\/173.4.1034","volume":"173","author":"H Marcotte","year":"1996","unstructured":"Marcotte, H. et al. Pneumocystis carinii infection in transgenic B cell-deficient mice. J. Infect. Dis. 173, 1034\u20131037 (1996).","journal-title":"J. Infect. Dis."},{"key":"BFnrneph2012107_CR63","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/acr.20279","volume":"62","author":"B Hugle","year":"2010","unstructured":"Hugle, B. et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res. 62, 1661\u20131664 (2010).","journal-title":"Arthritis Care Res."},{"key":"BFnrneph2012107_CR64","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1016\/j.amjmed.2005.06.012","volume":"118","author":"PK Wung","year":"2005","unstructured":"Wung, P. K. et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am. J. Med. 118, 1416 (2005).","journal-title":"Am. J. Med."},{"key":"BFnrneph2012107_CR65","first-page":"S648","volume":"52","author":"PK Wung","year":"2005","unstructured":"Wung, P. K. et al. Risk factors for herpes zoster in immunocompromised patients: experience from the Wegener's granulomatosis etanercept trial. Arthritis Rheum. 52, S648\u2013S649 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR66","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","volume":"22","author":"AM Evens","year":"2011","unstructured":"Evens, A. M. et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann. Oncol. 22, 1170\u20131180 (2011).","journal-title":"Ann. Oncol."},{"key":"BFnrneph2012107_CR67","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jbspin.2011.07.003","volume":"79","author":"E Ghrenassia","year":"2012","unstructured":"Ghrenassia, E., Mekinian, A., Rouaghe, S., Ganne, N. & Fain, O. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine 79, 100\u2013101 (2012).","journal-title":"Joint Bone Spine"},{"key":"BFnrneph2012107_CR68","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00296-009-1202-2","volume":"31","author":"A Pyrpasopoulou","year":"2011","unstructured":"Pyrpasopoulou, A. et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol. Int. 31, 403\u2013404 (2011).","journal-title":"Rheumatol. Int."},{"issue":"Suppl. 2","key":"BFnrneph2012107_CR69","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.3949\/ccjm.78.s2.07","volume":"78","author":"ES Molloy","year":"2011","unstructured":"Molloy, E. S. PML and rheumatology: the contribution of disease and drugs. Clev. Clin. J. Med. 78 (Suppl. 2), S28\u2013S32 (2011).","journal-title":"Clev. Clin. J. Med."},{"key":"BFnrneph2012107_CR70","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","volume":"68","author":"DB Clifford","year":"2011","unstructured":"Clifford, D. B. et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch. Neurol. 68, 1156\u20131164 (2011).","journal-title":"Arch. Neurol."},{"key":"BFnrneph2012107_CR71","doi-asserted-by":"crossref","unstructured":"Molloy, E. S. & Calabrese, L. H. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. doi:10.1002\/art.34468 (2012).","DOI":"10.1002\/art.34468"},{"key":"BFnrneph2012107_CR72","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/acr.21564","volume":"64","author":"A Bharat","year":"2012","unstructured":"Bharat, A. et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res. 64, 612\u2013615 (2012).","journal-title":"Arthritis Care Res."},{"key":"BFnrneph2012107_CR73","first-page":"S332","volume":"44","author":"AM Knight","year":"2001","unstructured":"Knight, A. M., Ekbom, A. & Askling, J. Cancer risk in a population based cohort of patients with Wegener's granulomatosis. Arthritis Rheum. 44, S332\u2013S332 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR74","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.V95842","volume":"9","author":"KWA Westman","year":"1998","unstructured":"Westman, K. W. A., Bygren, P. G., Olsson, H., Ranstam, J. & Wieslander, J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J. Am. Soc. Nephrol. 9, 842\u2013852 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2012107_CR75","first-page":"100","volume":"35","author":"M Faurschou","year":"2008","unstructured":"Faurschou, M. et al. Malignancies in Wegener's granulomatosis: Incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J. Rheumatol. 35, 100\u2013105 (2008).","journal-title":"J. Rheumatol."},{"key":"BFnrneph2012107_CR76","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1136\/ard.2010.145250","volume":"70","author":"C Heijl","year":"2011","unstructured":"Heijl, C. et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann. Rheum. Dis. 70, 1415\u20131421 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR77","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/art.30296","volume":"63","author":"G Le Guenno","year":"2011","unstructured":"Le Guenno, G. et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum. 63, 1435\u20131445 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR78","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1136\/ard.2003.019125","volume":"63","author":"A Knight","year":"2004","unstructured":"Knight, A., Askling, J., Granath, F., Sparen, P. & Ekbom, A. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann. Rheum. Dis. 63, 1307\u20131311 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneph2012107_CR79","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/art.22667","volume":"57","author":"R Nath","year":"2007","unstructured":"Nath, R. et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous Intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 57, 619\u2013625 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR80","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/rheumatology\/keh374","volume":"43","author":"T Pankhurst","year":"2004","unstructured":"Pankhurst, T., Savage, C. O. S., Gordon, C. & Harper, L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology 43, 1532\u20131535 (2004).","journal-title":"Rheumatology"},{"key":"BFnrneph2012107_CR81","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/rheumatology\/kep009","volume":"48","author":"M Faurschou","year":"2009","unstructured":"Faurschou, M. et al. Cancer preceding Wegeners granulomatosis: a casecontrol study. Rheumatology 48, 421\u2013424 (2009).","journal-title":"Rheumatology"},{"key":"BFnrneph2012107_CR82","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11926-011-0173-y","volume":"13","author":"D den Uyl","year":"2011","unstructured":"den Uyl, D., Bultink, I. E. M. & Lems, W. F. Advances in glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep. 13, 233\u2013240 (2011).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrneph2012107_CR83","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"Weinstein, R. S. Glucocorticoid-induced bone disease. N. Engl. J. Med. 365, 62\u201370 (2011).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2012107_CR84","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s198-002-8341-z","volume":"13","author":"MM Boomsma","year":"2002","unstructured":"Boomsma, M. M. et al. Prevalence of reduced bone mineral density in patients with antineutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos. Int. 13, 74\u201382 (2002).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2012107_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0149-2918(04)90001-X","volume":"26","author":"EP Boling","year":"2004","unstructured":"Boling, E. P. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis. Clin. Ther. 26, 1\u201314 (2004).","journal-title":"Clin. Ther."},{"key":"BFnrneph2012107_CR86","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.maturitas.2008.11.022","volume":"62","author":"J Compston","year":"2009","unstructured":"Compston, J. et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62, 105\u2013108 (2009).","journal-title":"Maturitas"},{"key":"BFnrneph2012107_CR87","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1590\/S1807-59322010001100024","volume":"65","author":"RM Rodrigues Pereira","year":"2010","unstructured":"Rodrigues Pereira, R. M., de Carvalho, J. F. & Canalis, E. Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics 65, 1197\u20131205 (2010).","journal-title":"Clinics"},{"key":"BFnrneph2012107_CR88","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","volume":"370","author":"BMP Tang","year":"2007","unstructured":"Tang, B. M. P., Eslick, G. D., Nowson, C., Smith, C. & Bensoussan, A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 370, 657\u2013666 (2007).","journal-title":"Lancet"},{"key":"BFnrneph2012107_CR89","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman, J. M. et al. American college of rheumatology recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 62, 1515\u20131526 (2010).","journal-title":"Arthritis Care Res."},{"key":"BFnrneph2012107_CR90","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi, J. D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids\u2014a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202\u2013211 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR91","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid, D. M. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253\u20131263 (2009).","journal-title":"Lancet"},{"key":"BFnrneph2012107_CR92","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00198-010-1372-5","volume":"22","author":"JC Netelenbos","year":"2011","unstructured":"Netelenbos, J. C., Geusens, P. P., Ypma, G. & Buijs, S. J. E. Adherence and profile of non-persistence in patients treated for osteoporosis\u2014a large-scale, long-term retrospective study in the Netherlands. Osteoporos. Int. 22, 1537\u20131546 (2011).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2012107_CR93","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00198-011-1549-6","volume":"29","author":"E Landfeldt","year":"2012","unstructured":"Landfeldt, E., Str\u00f6m, O., Robbins, S. & Borgstr\u00f6m, F. Adherence to treatment of primary osteoporosis and its association to fractures\u2014the Swedish Adherence Register Analysis (SARA). Osteoporos. Int. 29, 433\u2013443 (2012).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2012107_CR94","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1007\/s00198-006-0149-3","volume":"17","author":"ED Newman","year":"2006","unstructured":"Newman, E. D. et al. Glucocorticoid-induced osteoporosis program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos. Int. 17, 1428\u20131434 (2006).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2012107_CR95","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ncprheum0770","volume":"4","author":"MA Dooley","year":"2008","unstructured":"Dooley, M. A. & Nair, R. Therapy insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease. Nat. Clin. Pract. Rheumatol. 4, 250\u2013257 (2008).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"BFnrneph2012107_CR96","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1093\/humrep\/deh518","volume":"19","author":"KLT Schmidt","year":"2004","unstructured":"Schmidt, K. L. T. et al. Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples. Human Reprod. 19, 2806\u20132810 (2004).","journal-title":"Human Reprod."},{"key":"BFnrneph2012107_CR97","doi-asserted-by":"publisher","first-page":"366","DOI":"10.7326\/0003-4819-119-5-199309010-00003","volume":"119","author":"DT Boumpas","year":"1993","unstructured":"Boumpas, D. T. et al. Risk for sustained amenorrhea in patients with systemic lupus-erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med. 119, 366\u2013369 (1993).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2012107_CR98","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1002\/art.21117","volume":"52","author":"P Seo","year":"2005","unstructured":"Seo, P. et al. Damage caused by Wegener's granulomatosis and its treatment\u2014prospective data from the Wegener's granulomatosis Etanercept trial (WGET). Arthritis Rheum. 52, 2168\u20132178 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR99","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6","volume":"41","author":"CC Mok","year":"1998","unstructured":"Mok, C. C., Lau, C. S. & Wong, R. W. S. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 41, 831\u2013837 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR100","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.crohns.2011.01.009","volume":"5","author":"L Shim","year":"2011","unstructured":"Shim, L., Eslick, G. D., Simring, A. A., Murray, H. & Weltman, M. D. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J. Crohns Colitis 5, 234\u2013238 (2011).","journal-title":"J. Crohns Colitis"},{"key":"BFnrneph2012107_CR101","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2036.2006.03162.x","volume":"25","author":"V Langagergaard","year":"2007","unstructured":"Langagergaard, V., Pedersen, L., Gislum, M., Norgard, B. & Sorensen, H. T. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment. Pharmacol. Ther. 25, 73\u201381 (2007).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrneph2012107_CR102","unstructured":"Royal College of Physicians, The Royal College of Radiologists, Royal College of Obstetricians and Gynaecologists. The effects of cancer treatment on reproductive functions: guidance on management. Report of a Working Party. Royal College of Obstetricians and Gynaecologists [online] , (2007)."},{"key":"BFnrneph2012107_CR103","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/acr.20433","volume":"63","author":"R Suppiah","year":"2011","unstructured":"Suppiah, R. et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res. 63, 588\u2013596 (2011).","journal-title":"Arthritis Care Res."},{"key":"BFnrneph2012107_CR104","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1002\/art.24957","volume":"60","author":"MD Morgan","year":"2009","unstructured":"Morgan, M. D. et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides a matched-pair cohort study. Arthritis Rheum. 60, 3493\u20133500 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR105","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/art.23561","volume":"59","author":"PK Wung","year":"2008","unstructured":"Wung, P. K. et al. Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. Arthritis Rheum. 59, 746\u2013753 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrneph2012107_CR106","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","volume":"142","author":"PA Merkel","year":"2005","unstructured":"Merkel, P. A. et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's clinical occurrence of thrombosis (WeCLOT) study. Ann. Intern. Med. 142, 620\u2013626 (2005).","journal-title":"Ann. Intern. Med."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.107","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2012.107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:37:41Z","timestamp":1684471061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2012.107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,5]]},"references-count":106,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["BFnrneph2012107"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2012.107","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,5]]}}}